Zenotech Laboratories Ltd
BSE:532039
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Ekobot AB (publ)
STO:EKOBOT
|
SE |
Zenotech Laboratories Ltd
Note Receivable
Zenotech Laboratories Ltd
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Z
|
Zenotech Laboratories Ltd
BSE:532039
|
Note Receivable
₹64.6m
|
CAGR 3-Years
32%
|
CAGR 5-Years
49%
|
CAGR 10-Years
7%
|
|
|
Transgene Biotek Ltd
BSE:526139
|
Note Receivable
₹230.2m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Hester Biosciences Ltd
NSE:HESTERBIO
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biocon Ltd
NSE:BIOCON
|
Note Receivable
₹3.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
6%
|
CAGR 10-Years
0%
|
|
|
Panacea Biotec Ltd
NSE:PANACEABIO
|
Note Receivable
₹97.9m
|
CAGR 3-Years
12%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
Zenotech Laboratories Ltd
Glance View
Zenotech Laboratories Ltd. engages in the manufacture and marketing of pharmaceuticals products. The company is headquartered in Hyderabad, Telangana. The firm is engaged in the business of manufacturing and marketing biotechnology and pharmaceuticals products. The Company’s injectables product portfolio primarily serves niche therapy areas, such as oncology and anesthesiology. The firm has a manufacturing facility at Turkapally village, Shamirpet Mandal, Telangana.
See Also
What is Zenotech Laboratories Ltd's Note Receivable?
Note Receivable
64.6m
INR
Based on the financial report for Dec 31, 2025, Zenotech Laboratories Ltd's Note Receivable amounts to 64.6m INR.
What is Zenotech Laboratories Ltd's Note Receivable growth rate?
Note Receivable CAGR 10Y
7%
Over the last year, the Note Receivable growth was 20%. The average annual Note Receivable growth rates for Zenotech Laboratories Ltd have been 32% over the past three years , 49% over the past five years , and 7% over the past ten years .
